Benitec Biopharma (BNTC) Cash & Equivalents (2019 - 2025)

Benitec Biopharma (BNTC) has 7 years of Cash & Equivalents data on file, last reported at $188.8 million in Q4 2025.

• For the quarter ending Q4 2025, Cash & Equivalents rose 141.18% year-over-year to $188.8 million; the trailing twelve-month figure through Dec 2025 stood at $188.8 million (up 141.18% YoY), and the FY2025 full-year result was $97.7 million, up 92.16% from the prior year.
• Cash & Equivalents improved to $188.8 million in Q4 2025, from $94.5 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $188.8 million in Q4 2025 to a low of $2.5 million in Q2 2023.
• A 5-year average of $44.0 million and a median of $19.8 million in 2021 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents tumbled 79.45% in 2022 and surged 1953.53% in 2024, its largest moves.
• Tracing BNTC's Cash & Equivalents over 5 years: stood at $12.3 million in 2021, then decreased by 14.53% to $10.5 million in 2022, then jumped by 93.36% to $20.4 million in 2023, then jumped by 284.23% to $78.3 million in 2024, then jumped by 141.18% to $188.8 million in 2025.
• Business Quant data shows BNTC's Cash & Equivalents at $188.8 million in Q4 2025, $94.5 million in Q3 2025, and $97.7 million in Q2 2025.